Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 2: Predictors of relapse during the continuation phase of pharmacotherapy

George I. Papakostas, Timothy Petersen, David Mischoulon, Cassandra H. Green, Andrew A. Nierenberg, Teodoro Bottiglieri, Jerrold F. Rosenbaum, Jonathan E. Alpert, Maurizio Fava

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Objective: In the present study, we assessed the relationship between serum folate, vitamin B12, and homocysteine levels on the rate of relapse in outpatients with remitted major depressive disorder (MDD) during a 28-week continuation phase of treatment with fluoxetine. Method: Seventy-one outpatients (mean ± SD age = 40.2 ± 11.1 years; 56.3% women) with MDD (as assessed with the Structured Clinical Interview for DSM-III-R) who had remitted and who were enrolled in the continuation phase of treatment with fluoxetine had serum folate, vitamin B12, and homocysteine measurements completed at baseline (prior to acute-phase treatment). Patients were followed for 28 weeks of continued treatment with fluoxetine 40 mg/day to monitor for depressive relapse. Folate levels were classified as either low (≤ 2.5 ng/mL) or normal. Vitamin B12 levels were classified as either low (≤ 200 pg/mL) or normal. Homocysteine levels were classified as either elevated (≥ 13.2 μmol/L) or normal. With the use of separate logistic regressions, we then assessed the relationship between folate, vitamin B12, and homocysteine level status and relapse. The study was conducted from November 1992 to January 1999. Results: The presence of low serum folate levels (p = .004), but not low B12 (p > .05) or elevated homocysteine levels (p > .05), was associated with relapse during continuation treatment with fluoxetine. The relapse rates for patients with (N = 7) and without (N = 64) low folate levels were 42.9% versus 3.2%, respectively. Conclusion: Low serum folate levels were found to place patients with remitted MDD at risk for depressive relapse during the continuation phase of treatment with fluoxetine.

Original languageEnglish (US)
Pages (from-to)1096-1098
Number of pages3
JournalJournal of Clinical Psychiatry
Volume65
Issue number8
DOIs
StatePublished - Aug 2004
Externally publishedYes

Fingerprint

Homocysteine
Vitamin B 12
Folic Acid
Fluoxetine
Recurrence
Drug Therapy
Serum
Major Depressive Disorder
Outpatients
Therapeutics
Major Depressive Disorder 2
Diagnostic and Statistical Manual of Mental Disorders
Logistic Models
Interviews

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology

Cite this

Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 2 : Predictors of relapse during the continuation phase of pharmacotherapy. / Papakostas, George I.; Petersen, Timothy; Mischoulon, David; Green, Cassandra H.; Nierenberg, Andrew A.; Bottiglieri, Teodoro; Rosenbaum, Jerrold F.; Alpert, Jonathan E.; Fava, Maurizio.

In: Journal of Clinical Psychiatry, Vol. 65, No. 8, 08.2004, p. 1096-1098.

Research output: Contribution to journalArticle

Papakostas, GI, Petersen, T, Mischoulon, D, Green, CH, Nierenberg, AA, Bottiglieri, T, Rosenbaum, JF, Alpert, JE & Fava, M 2004, 'Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 2: Predictors of relapse during the continuation phase of pharmacotherapy', Journal of Clinical Psychiatry, vol. 65, no. 8, pp. 1096-1098. https://doi.org/10.4088/JCP.v65n0811
Papakostas, George I. ; Petersen, Timothy ; Mischoulon, David ; Green, Cassandra H. ; Nierenberg, Andrew A. ; Bottiglieri, Teodoro ; Rosenbaum, Jerrold F. ; Alpert, Jonathan E. ; Fava, Maurizio. / Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 2 : Predictors of relapse during the continuation phase of pharmacotherapy. In: Journal of Clinical Psychiatry. 2004 ; Vol. 65, No. 8. pp. 1096-1098.
@article{6659fcf1359c4875a5bfcebfa06e8861,
title = "Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 2: Predictors of relapse during the continuation phase of pharmacotherapy",
abstract = "Objective: In the present study, we assessed the relationship between serum folate, vitamin B12, and homocysteine levels on the rate of relapse in outpatients with remitted major depressive disorder (MDD) during a 28-week continuation phase of treatment with fluoxetine. Method: Seventy-one outpatients (mean ± SD age = 40.2 ± 11.1 years; 56.3{\%} women) with MDD (as assessed with the Structured Clinical Interview for DSM-III-R) who had remitted and who were enrolled in the continuation phase of treatment with fluoxetine had serum folate, vitamin B12, and homocysteine measurements completed at baseline (prior to acute-phase treatment). Patients were followed for 28 weeks of continued treatment with fluoxetine 40 mg/day to monitor for depressive relapse. Folate levels were classified as either low (≤ 2.5 ng/mL) or normal. Vitamin B12 levels were classified as either low (≤ 200 pg/mL) or normal. Homocysteine levels were classified as either elevated (≥ 13.2 μmol/L) or normal. With the use of separate logistic regressions, we then assessed the relationship between folate, vitamin B12, and homocysteine level status and relapse. The study was conducted from November 1992 to January 1999. Results: The presence of low serum folate levels (p = .004), but not low B12 (p > .05) or elevated homocysteine levels (p > .05), was associated with relapse during continuation treatment with fluoxetine. The relapse rates for patients with (N = 7) and without (N = 64) low folate levels were 42.9{\%} versus 3.2{\%}, respectively. Conclusion: Low serum folate levels were found to place patients with remitted MDD at risk for depressive relapse during the continuation phase of treatment with fluoxetine.",
author = "Papakostas, {George I.} and Timothy Petersen and David Mischoulon and Green, {Cassandra H.} and Nierenberg, {Andrew A.} and Teodoro Bottiglieri and Rosenbaum, {Jerrold F.} and Alpert, {Jonathan E.} and Maurizio Fava",
year = "2004",
month = "8",
doi = "10.4088/JCP.v65n0811",
language = "English (US)",
volume = "65",
pages = "1096--1098",
journal = "Journal of Clinical Psychiatry",
issn = "0160-6689",
publisher = "Physicians Postgraduate Press Inc.",
number = "8",

}

TY - JOUR

T1 - Serum folate, vitamin B12, and homocysteine in major depressive disorder, part 2

T2 - Predictors of relapse during the continuation phase of pharmacotherapy

AU - Papakostas, George I.

AU - Petersen, Timothy

AU - Mischoulon, David

AU - Green, Cassandra H.

AU - Nierenberg, Andrew A.

AU - Bottiglieri, Teodoro

AU - Rosenbaum, Jerrold F.

AU - Alpert, Jonathan E.

AU - Fava, Maurizio

PY - 2004/8

Y1 - 2004/8

N2 - Objective: In the present study, we assessed the relationship between serum folate, vitamin B12, and homocysteine levels on the rate of relapse in outpatients with remitted major depressive disorder (MDD) during a 28-week continuation phase of treatment with fluoxetine. Method: Seventy-one outpatients (mean ± SD age = 40.2 ± 11.1 years; 56.3% women) with MDD (as assessed with the Structured Clinical Interview for DSM-III-R) who had remitted and who were enrolled in the continuation phase of treatment with fluoxetine had serum folate, vitamin B12, and homocysteine measurements completed at baseline (prior to acute-phase treatment). Patients were followed for 28 weeks of continued treatment with fluoxetine 40 mg/day to monitor for depressive relapse. Folate levels were classified as either low (≤ 2.5 ng/mL) or normal. Vitamin B12 levels were classified as either low (≤ 200 pg/mL) or normal. Homocysteine levels were classified as either elevated (≥ 13.2 μmol/L) or normal. With the use of separate logistic regressions, we then assessed the relationship between folate, vitamin B12, and homocysteine level status and relapse. The study was conducted from November 1992 to January 1999. Results: The presence of low serum folate levels (p = .004), but not low B12 (p > .05) or elevated homocysteine levels (p > .05), was associated with relapse during continuation treatment with fluoxetine. The relapse rates for patients with (N = 7) and without (N = 64) low folate levels were 42.9% versus 3.2%, respectively. Conclusion: Low serum folate levels were found to place patients with remitted MDD at risk for depressive relapse during the continuation phase of treatment with fluoxetine.

AB - Objective: In the present study, we assessed the relationship between serum folate, vitamin B12, and homocysteine levels on the rate of relapse in outpatients with remitted major depressive disorder (MDD) during a 28-week continuation phase of treatment with fluoxetine. Method: Seventy-one outpatients (mean ± SD age = 40.2 ± 11.1 years; 56.3% women) with MDD (as assessed with the Structured Clinical Interview for DSM-III-R) who had remitted and who were enrolled in the continuation phase of treatment with fluoxetine had serum folate, vitamin B12, and homocysteine measurements completed at baseline (prior to acute-phase treatment). Patients were followed for 28 weeks of continued treatment with fluoxetine 40 mg/day to monitor for depressive relapse. Folate levels were classified as either low (≤ 2.5 ng/mL) or normal. Vitamin B12 levels were classified as either low (≤ 200 pg/mL) or normal. Homocysteine levels were classified as either elevated (≥ 13.2 μmol/L) or normal. With the use of separate logistic regressions, we then assessed the relationship between folate, vitamin B12, and homocysteine level status and relapse. The study was conducted from November 1992 to January 1999. Results: The presence of low serum folate levels (p = .004), but not low B12 (p > .05) or elevated homocysteine levels (p > .05), was associated with relapse during continuation treatment with fluoxetine. The relapse rates for patients with (N = 7) and without (N = 64) low folate levels were 42.9% versus 3.2%, respectively. Conclusion: Low serum folate levels were found to place patients with remitted MDD at risk for depressive relapse during the continuation phase of treatment with fluoxetine.

UR - http://www.scopus.com/inward/record.url?scp=4544255446&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4544255446&partnerID=8YFLogxK

U2 - 10.4088/JCP.v65n0811

DO - 10.4088/JCP.v65n0811

M3 - Article

C2 - 15323595

AN - SCOPUS:4544255446

VL - 65

SP - 1096

EP - 1098

JO - Journal of Clinical Psychiatry

JF - Journal of Clinical Psychiatry

SN - 0160-6689

IS - 8

ER -